SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997; 89: 39093918.
  • 2
    Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993; 20: 7588.
  • 3
    Hiddemann W, Dreyling MH, Tiemann M, Schrader C, Unterhalt M. Mantle cell lymphomas. Haematologica. 1999; 84: 9395.
  • 4
    Weisenburger DD, Armitage JO. Mantle cell lymphoma—an entity comes of age. Blood. 1996; 87: 44834494.
  • 5
    Zucca E, Roggero E, Pinotti G, et al. Patterns of survival in mantle cell lymphoma. Ann Oncol. 1995; 6: 257262.
  • 6
    Hiddemann W, Dreyling M. Mantle cell lymphoma: therapeutic strategies are different from CLL. Curr Treat Options Oncol. 2003; 4: 219226.
  • 7
    Hiddemann W, Dreyling MH, Pfreundschuh M, et al. Myeloablative radiochemotherapy followed by autologous blood stem cell transplantation leads to a significant prolongation of the event-free survival in patients with mantle cell lymphoma (MCL)—results of a prospective randomized European intergroup study [abstract]. Blood. 2001; 98: 861.
  • 8
    Khouri IF, Saliba RM, Okoroji GJ, Acholonu SA, Champlin RE. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of β2-microglobulin and the tumor score. Cancer. 2003; 98: 26302635.
  • 9
    Romaguera JE, Khouri IF, Kantarjian HM, et al. Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. Leuk Lymphoma. 2000; 39: 7785.
  • 10
    Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989; 74: 1925.
  • 11
    Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000; 343: 17501757.
  • 12
    Leblond V, Levy V, Maloisel F, et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood. 2001; 98: 26402644.
  • 13
    Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002; 41: 93103.
  • 14
    Bellosillo B, Villamor N, Colomer D, Pons G, Montserrat E, Gil J. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia. Blood. 1999; 94: 28362843.
  • 15
    Koehl U, Li L, Nowak B, et al. Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross-link removal [abstract]. Proc Am Soc Clin Oncol. 1997; 38: A10.
  • 16
    Manches O, Lui G, Chaperot L, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003; 101: 949954.
  • 17
    Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003; 22: 73597368.
  • 18
    Di Gaetano N, Xiao Y, Erba E, et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol. 2001; 114: 800809.
  • 19
    Hagenbeek A, Eghbali H, Mondfardini S, et al. Fludarabine compared with CVP chemotherapy in newly diagnosed patients with Stages III and IV low grade malignant non-Hodgkin's lymphoma. Final analysis of a prospective randomized Phase III intergroup study in 381 patients [abstract]. Blood. 2001; 98: 3501.
  • 20
    Hiddemann W, Unterhalt M, Pott C, et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a Phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group. Semin Oncol. 1993; 20: 2831.
  • 21
    Solal-Celigny P, Brice P, Brousse N, et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1996; 14: 514519.
  • 22
    Foran JM, Rohatiner AZ, Coiffier B, et al. Multicenter Phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol. 1999; 17: 546553.
  • 23
    Redman JR, Cabanillas F, Velasquez WS, et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992; 10: 790794.
  • 24
    Zinzani PL, Magagnoli M, Moretti L, et al. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. J Clin Oncol. 2000; 18: 773779.
  • 25
    Gamberale R, Galmarini CM, Fernandez-Calotti P, et al. In vitro susceptibility of CD4+ and CD8+ T cell subsets to fludarabine. Biochem Pharmacol. 2003; 66: 21852191.
  • 26
    Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol. 1993; 50: 292296.
  • 27
    Klasa RJ, Meyer RM, Shustik C, et al. Randomized Phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol. 2002; 20: 46494954.
  • 28
    Cohen BJ, Moskowitz C, Straus D, Noy A, Hedrick E, Zelenetz A. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma. 2001; 42: 10151022.
  • 29
    Crawley CR, Foran JM, Gupta RK, et al. A Phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma. Ann Oncol. 2000; 11: 861865.
  • 30
    Eucker J, Schille C, Schmid P, et al. The combination of fludarabine and cyclophosphamide results in a high remission rate with moderate toxicity in low-grade non-Hodgkin's lymphomas. Anticancer Drugs. 2002; 13: 907913.
  • 31
    Emmanouilides C, Rosen P, Rasti S, Territo M, Kunkel L. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a Phase II trial. Hematol Oncol. 1998; 16: 107116.
  • 32
    Velasquez WS, Lew D, Grogan TM, et al. Combination of fludarabine and mitoxantrone in untreated Stages III and IV low-grade lymphoma: S9501. J Clin Oncol. 2003; 21: 19962003.
  • 33
    Abruzzo LV, Rosales CM, Medeiros LJ, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol. 2002; 26: 630636.
  • 34
    Lazzarino M, Orlandi E, Baldanti F, et al. The immunosuppression and potential for EBV reactivation of fludarabine combined with cyclophosphamide and dexamethasone in patients with lymphoproliferative disorders. Br J Haematol. 1999; 107: 877882.
  • 35
    Seymour JF, Wolf M, Grigg AP, Januszewicz E, Prince H, Westerman D. Predictive factors for infectious complications in patients with lymphoproliferative disorders treated with fludarabine combinations without corticosteroids [abstract]. Ann Oncol. 2002; 13: 194.
  • 36
    McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996; 14: 12621268.
  • 37
    Tsimberidou AM, McLaughlin P, Younes A, et al. Fludarabine, mitoxantrone, dexamethasone (FND) compared with an alternating triple therapy (ATT) regimen in patients with Stage IV indolent lymphoma. Blood. 2002; 100: 43514357.
  • 38
    Byrd JC, Hargis JB, Kester KE, Hospenthal DR, Knutson SW, Diehl LF. Opportunistic pulmonary infections with fludarabine in previously treated patients with low-grade lymphoid malignancies: a role for Pneumocystis carinii pneumonia prophylaxis. Am J Hematol. 1995; 49: 135142.
  • 39
    Spriano M, Chisesi T, Majolino AI, et al. Fludarabine/cytoxan/mitoxantrone (FLU/CY/MITO) as front-line therapy in low-grade NHL (LGL) [abstract]. Ann Oncol. 2002; 13: 502.
  • 40
    Hochster HS, Oken MM, Winter JN, et al. Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: results and and [sic] long-term follow-up—a report from the Eastern Cooperative Oncology Group. J Clin Oncol. 2000; 18: 987994.
  • 41
    Morrison VA, Rai KR, Peterson BL, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup study Cancer and Leukemia Group B 9011. J Clin Oncol. 2001; 19: 36113621.
  • 42
    Byrd JC, McGrail LH, Hospenthal DR, Howard RS, Dow NA, Diehl LF. Herpes virus infections occur frequently following treatment with fludarabine: results of a prospective natural history study. Br J Haematol. 1999; 105: 445447.
  • 43
    Weiss RB, Freiman J, Kweder SL, Diehl LF, Byrd JC. Hemolytic anemia after fludarabine therapy for chronic lymphocytic leukemia. J Clin Oncol. 1998; 16: 18851889.
  • 44
    Myint H, Copplestone JA, Orchard J, et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol. 1995; 91: 341344.
  • 45
    Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000; 96: 7175.
  • 46
    Tournilhac O, Cazin B, Lepretre S, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood. 2004; 103: 363365.
  • 47
    Visani G, Lemoli RM, Tosi P, et al. Fludarabine-containing regimens severely impair peripheral blood stem cells mobilization and collection in acute myeloid leukaemia patients. Br J Haematol. 1999; 105: 775779.
  • 48
    Laszlo D, Galieni P, Raspadori D, et al. Fludarabine containing-regimens may adversely affect peripheral blood stem cell collection in low-grade non Hodgkin lymphoma patients. Leuk Lymphoma. 2000; 37: 157161.
  • 49
    Morrison VA, Rai KR, Peterson BL, et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, Cancer and Leukemia Group B 9011. J Clin Oncol. 2002; 20: 38783884.
  • 50
    Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol. 1999; 17: 24542460.
  • 51
    Misgeld E, Germing U, Aul C, Gattermann N. Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma. Leuk Res. 2001; 25: 9598.
  • 52
    Dreyling MH, Forstpointner R, Repp R, et al. Combined immuno-chemotherapy (R-FCM) results in superior remission and survival rates in recurrent follicular and mantle cell lymphoma—final results of a prospective randomized trial of the GLSG [abstract]. Hematol J. 2003; 4: 484.
  • 53
    Zinzani PL. A multicenter randomized trial of fludarabine and mitoxantrone (FM) plus rituximab versus CHOP plus rituximab as first-line treatment in patients with follicular lymphoma (FL) [abstract]. Blood. 2002; 100: 344.
  • 54
    Vitolo U, Boccomini C, Ladetto M, et al. High clinical and molecular response rate in elderly patients with advanced stage follicular lymphoma treated at diagnosis with a brief chemo-immunotherapy FND + rituximab [abstract]. Blood. 2002; 100: 1392.
  • 55
    Sacchi S, Tucci A, Merli F, et al. Phase II study with fludarabine and cyclophosphamide puls rituximab (FC+R) in relapsed follicular lymphoma patients [abstract]. Blood. 2002; 100: 2246.
  • 56
    Cohen A, Polliack A, Ben-Bassat I, et al. Results of a Phase II study employing a combination of fludarabine, cyclophosphamide and rituximab (FCR) as primary therapy for patients with advanced follicluar lymphoma (FL): the Israel Cooperative Lymphoma Group [abstract]. Blood. 2002; 100: 1393.
  • 57
    Byrd JC, Peterson BL, Morrison VA, et al. Randomized Phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003; 101: 614.
  • 58
    McLaughlin P, Rodriguez A, Hagemeister F, et al. Stage IV indolent lymphoma: a randomized study of concurrent vs. sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance [abstract]. Proc Am Soc Clin Oncol. 2003; 22: 564.
  • 59
    Coiffier B, Neidhardt-Berard EM, Tilly H, et al. Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol. 1999; 10: 11911197.
  • 60
    Keating MJ, McLaughlin P, Cabanillas F. Low-grade non-Hodgkin's lymphoma—development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND). Eur J Cancer Care (Engl). 1997; 6 (4 Suppl): 2126.
  • 61
    Decaudin D, Bosq J, Tertian G, et al. Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol. 1998; 16: 579583.
  • 62
    Bosch F, Perales M, Cobo F. Fludarabine, cyclophosphamide and mitoxantrone (FCM) therapy in resistant or relapsed chronic lymphocytic leukemia (CLL) or follicular lymphoma (FL) [abstract]. Blood. 1997; 90: 530a.
  • 63
    Montoto S, Lopez-Guillermo A, Domingo-Domenech E, et al. Fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen as first-line therapy in younger patients with advanced stage follicular lymphoma (FL) [abstract]. Ann Oncol. 2002; 13: 184.
  • 64
    Zinzani PL, Bendandi M, Magagnoli M, Gherlinzoni F, Merla E, Tura S. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol. 1997; 8: 379383.
  • 65
    Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997; 90: 21882195.
  • 66
    McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998; 16: 28252833.
  • 67
    Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001; 97: 101106.
  • 68
    Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood. 2004; 103: 44164423.
  • 69
    Czuczman MS, Fallon A, Mohr A, et al. Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Semin Oncol. 2002; 29: 3640.
  • 70
    Foran JM, Rohatiner AZ, Cunningham D, et al. European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000; 18: 317324.
  • 71
    Ghielmini M, Schmitz SF, Burki K, et al. The effect of rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2000; 11: 123126.
  • 72
    Tobinai K. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan. Int J Hematol. 2002; 76: 411419.
  • 73
    Whelan JS, Davis CL, Rule S, et al. Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer. 1991; 64: 120123.
  • 74
    Seymour JF, Grigg AP, Szer J, Fox RM. Cisplatin, fludarabine, and cytarabine: a novel, pharmacologically designed salvage therapy for patients with refractory, histologically aggressive or mantle cell non-Hodgkin's lymphoma. Cancer. 2002; 94: 585593.